SCHEMBL7150490

SCHEMBL7150490

COC(=O)c1ccc(NCC(=O)CN(C)C(=O)C2CC(SC(C)=O)CN2S(=O)(=O)CCc2cccc3ccccc23)cc1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MME P08473 1/20 0.33
ACE P12821 1/20 0.33
ECE1 P42892 1/20 0.33
PNKP Q96T60 1/20 0.33
ALDH1A1 P00352 3/20 0.32
RAB9A P51151 3/20 0.32
NPC1 O15118 1/20 0.32
HPGD P15428 1/20 0.32
AGTR1 P30556 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HTR6 P50406 1/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
KMT2A Q03164 1/20 0.31
ALOX5 P09917 1/20 0.31
MTNR1A P48039 1/20 0.30
MTNR1B P49286 1/20 0.30
TAOK1 Q7L7X3 1/20 0.30
GFER P55789 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7150494 0.88 MME (0.34) MMEACEECE1MTNR1AMTNR1B
SCHEMBL7150497 0.88 MME (0.34) MMEACEECE1MTNR1AMTNR1B
SCHEMBL7144462 0.87 MME (0.38) MMEACEECE1ALDH1A1RAB9A
SCHEMBL7148392 0.85 CA1 (0.38) MMEACEECE1ALDH1A1RAB9A
SCHEMBL7148898 0.83 MME (0.40) MMEACEECE1ALDH1A1RAB9A
SCHEMBL7145216 0.80 MME (0.40) MMEACEECE1ALDH1A1RAB9A
SCHEMBL7144605 0.80 ALDH1A1 (0.36) MMEACEECE1ALDH1A1RAB9A
SCHEMBL7143826 0.80 ALDH1A1 (0.46) ALDH1A1HPGDSMN1; SMN2LMNAMAPT
SCHEMBL7140488 0.79 ALDH1A1 (0.40) MMEACEECE1ALDH1A1RAB9A
SCHEMBL7140148 0.78 MME (0.38) MMEACEECE1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303485-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed
WO-2002006222-A1 PYRROLIDINE DERIVATIVES AS INHIBITORS OF ENDOTHELIN-CONVERTING ENZYME F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP MME 99/4885ACE 44/4885ECE1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.